ImmunoCellular receives 'buy' rating from Summer Street research
ImmunoCellular Therapies has received a 'buy' rating from Summer Street Research Partners, based largely on its ICT-107 vaccine product, used to treat patients with newly diagnosed glioblastoma multiforme, a common and aggressive form of malignant brain tumor.
Virginia public health officials say immunization rates for children and adolescents have significantly improved for most vaccines.